Regeneron extends BARDA Inmazeb supply deal, adds $270m through 2031
Regeneron Pharmaceuticals has extended its procurement agreement with the Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of Inmazeb, its approved three-antibody Ebola treatment, to the US government. The amended deal adds approximately $270 million in value and runs through 2031, building on a partnership first established in 2020.
Inmazeb, a cocktail of atoltivimab, maftivimab, and odesivimab-ebgn, was the first treatment approved by the US Food and Drug Administration specifically for infection caused by Orthoebolavirus zairense, the strain responsible for most Ebola outbreaks. Its approval in 2020 was supported by the 681-patient PALM Trial, conducted during the 2018 Democratic Republic of Congo (DRC) outbreak; results published in the New England Journal of Medicine showed Inmazeb reduced mortality by approximately 55 per cent compared to an active control in patients with low viral load. The trial was stopped early following a pre-specified interim analysis demonstrating superiority.
Expanding the stockpile
Leonard Schleifer, board co-chair, president and chief executive of Regeneron, said maintaining a ready supply of Inmazeb was "exactly the kind of preparedness this country needs for the threats we can already see on the horizon." The extended agreement, he said, reflects a shared commitment with BARDA to ensuring medicines are available whenever an outbreak occurs.
BARDA's involvement is significant beyond the commercial arrangement. The authority, which sits within the Administration for Strategic Preparedness and Response at the Department of Health and Human Services, has a mandate to build US medical countermeasure stockpiles for biological, chemical, radiological, and nuclear threats. Inmazeb's inclusion in that stockpile, alongside WHO prequalification achieved in November 2023, positions it as the global reference standard for Ebola treatment.
Maftivimab and the Bundibugyo outbreak
Separately, Regeneron announced that maftivimab, the most potent virus-neutralising component of Inmazeb, is being added to the PARTNERS platform adaptive trial to evaluate its potential in the current Bundibugyo virus disease outbreak in the DRC. Bundibugyo is a distinct orthoebolavirus species for which no approved treatment currently exists.
Preclinical data supporting the move, including in vitro and non-human primate studies, have been posted as a preprint on BioRxiv and are pending peer-reviewed publication. The PARTNERS trial is coordinated internationally by the Pandemic Sciences Institute at the University of Oxford, led nationally by the Institut National de Recherche Biomédicale in the DRC, and sponsored by the World Health Organization.
George Yancopoulos, board co-chair, president and chief scientific officer, said Regeneron was advancing maftivimab "as quickly as possible to help in the current outbreak," citing the company's VelociSuite rapid-response platform as enabling accelerated candidate generation.
Market and policy context
The Inmazeb procurement extension sits within a broader US government effort to secure medical countermeasures against high-consequence pathogens. BARDA has used similar long-term supply agreements for anthrax antitoxins and smallpox antivirals, creating predictable revenue streams for developers willing to invest in infectious disease preparedness, a historically underfunded area relative to commercial markets.
For Regeneron, the $270 million addition is modest against a revenue base that runs to several billion dollars annually, but it reinforces the strategic value of its infectious disease platform at a time when the company is navigating pricing pressures in its larger commercial franchises. The parallel maftivimab development programme, if successful in PARTNERS, could extend the commercial and humanitarian reach of the Inmazeb antibody family across multiple Ebola species and strengthen Regeneron's position as the primary industrial partner for global Ebola response.